Recent Updates
Recently added Catalysts
HRMY Positive Sentiment

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Tuesday, March 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Harmony Biosciences will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The management team will engage in a fireside chat, which will be accessible via a webcast. This event highlights the company's commitment to developing therapies for rare neurological diseases.
Price reaction · baseline $26.9 (2026-03-30 close) · hit after-hours · 1 other HRMY headline(s) in the window, move may be shared
day 0 close · peak
+4.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable healthcare conference.
  • Opportunity to showcase innovative therapies.
  • Engagement with investors and stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
3.4%
average across 4 past catalysts
Lead asset
Clemizole
Phase 3 · Lennox Gastaut Syndrome

Full Press Release Details

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25thAnnual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website athttps://ir.harmonybiosciences.com/.
About Harmony BiosciencesHarmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visitwww.harmonybiosciences.com.

Frequently Asked Questions

When is Harmony Biosciences participating in the conference?

Harmony Biosciences will participate on April 13, 2026, at 9:30 a.m. ET.

Where can I watch the fireside chat?

The fireside chat will be available on Harmony Biosciences' investor page.

What is the focus of Harmony Biosciences?

Harmony Biosciences focuses on developing therapies for rare neurological diseases.

Who established Harmony Biosciences?

Harmony Biosciences was established by Paragon Biosciences, LLC in 2017.

ShareAdd on Google
Tags: HRMY Viatris Investor Conferences Healthcare Harmony Biosciences Needham Conference healthcare neurological diseases
Last updated: Mar 31, 2026

Biotech snapshot

Cash runway
$668M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ClemizolePhase 3
Lennox Gastaut Syndrome →

Catalyst track record

+43%
best trade around HRMY's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for HRMY.

See every catalyst's timing & PoA →